TherapeuticsMD Inc. (NASDAQ:TXMD) shares, rose in value on Friday, 05/13/22, with the stock price up by 3.02% to the previous day’s close as strong demand from buyers drove the stock to $3.07.
Actively observing the price movement in the last trading, the stock closed the session at $2.98, falling within a range of $2.97 and $3.3595. The value of beta (5-year monthly) was 1.75. Referring to stock’s 52-week performance, its high was $69.50, and the low was $2.86. On the whole, TXMD has fluctuated by -79.64% over the past month.
With the market capitalization of TherapeuticsMD Inc. currently standing at about $1.50 billion, investors are eagerly awaiting this quarter’s results, scheduled for Feb 28, 2022 – Mar 04, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.07, which is expected to increase to -$0.05 for fiscal year -$0.4 and then to about -$0.15 by fiscal year 2022. Data indicates that the EPS growth is expected to be 40.30% in 2022, while the next year’s EPS growth is forecast to be 62.50%.
Analysts have estimated the company’s revenue for the quarter at $28.98 million, with a low estimate of $27.9 million and a high estimate of $30.07 million. According to the average forecast, sales growth in current quarter could jump up 28.40%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $96.67 million, representing an increase of 49.00% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that TXMD’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of TXMD currently trading nearly -68.18% and -78.53% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 13.83, while the 7-day volatility ratio is showing 34.84% which for the 30-day chart, stands at 16.48%. Furthermore, TherapeuticsMD Inc. (TXMD)’s beta value is 2.10, and its average true range (ATR) is 1.24.
A comparison of TherapeuticsMD Inc. (TXMD) with its peers suggests the former has fared considerably weaker in the market. TXMD showed an intraday change of 3.02% in last session, and over the past year, it shrunk by -94.15%%. In comparison, AbbVie Inc. (ABBV) has moved lower at -0.51% on the day and was up 31.84% over the past 12 months. On the other hand, the price of Pfizer Inc. (PFE) has fallen -0.93% on the day. The stock, however, is off 24.74% from where it was a year ago. Additionally, there is a loss of -1.21% for Agile Therapeutics Inc. (AGRX) in last trading while the stock has seen an overall depriciation of -97.47%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 2.39%. Meanwhile, the Dow Jones Industrial Improved by 1.47%.
Data on historical trading for TherapeuticsMD Inc. (NASDAQ:TXMD) indicates that the trading volumes over the past 3 months, they’ve averaged 230.82K. According to company’s latest data on outstanding shares, there are 427.63 million shares outstanding.
Nearly 0.60% of TherapeuticsMD Inc.’s shares belong to company insiders and institutional investors own 33.80% of the company’s shares. The stock has fallen by -82.73% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TXMD stock heading into the next quarter.